Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial of Bortezomib Induction and Maintenance in Patients with Newly Diagnosed MM

Conference Correspondent  - Conference Correspondent, ASH

High-dose melphalan (HDM) followed by autologous stem-cell transplantation (ASCT) is the standard of care for transplant-eligible patients with multiple myeloma (MM). Sonneveld and colleagues reported the long-term follow-up results of the HOVON-65/GMMG-HD4 trial, which had previously demonstrated bortezomib-based induction and maintenance regimens followed by HDM and ASCT significantly improved survival outcomes in transplant-eligible patients with newly diagnosed MM compared with standard.1,2 The HOVON-65/GMMG-HD4 trial randomized 827 eligible patients to standard induction therapy with vincristine/doxorubicin/dexamethasone or the bortezomib-based bortezomib/doxorubicin/dexamethasone regimen, followed by HDM/ASCT. Patients received maintenance therapy with a daily thalidomide regimen (control) or twice-weekly bortezomib treatment in the experimental arm for 2 years.  

At a median follow-up of 91.4 months, patients who received bortezomib-based regimen achieved significantly higher rates of complete response (37% vs 25%),  ≥very good partial response (26% vs 21%), and overall response rate (91% vs 83%) compared with the standard regimen. Median progression-free survival (PFS) was significantly prolonged with bortezomib-based regimen (34 months vs 28 months; hazard ratio, 0.77; P = .001) compared with standard regimen. However, this PFS benefit did not translate into an improvement in overall survival (OS; median OS: 90 months vs 83 months) in the primary analysis, although a significant prolongation by 4.8 months was observed in a univariate analysis (P = .04). The bortezomib-containing cohort derived a significant OS benefit at 60 months with double HDM/ASCT (71% vs 60%; P = .04), whereas administration of single versus double HDM/ASCT did not provide PFS benefit at 60 months. Subgroup analysis (n = 395) based on presence or absence of adverse chromosomal abnormalities found that bortezomib treatment plus double HDM/ASCT in the subset of patients with del(17p) significantly improved PFS and OS, while it did not benefit patients with t(4;14) and add(1q) abnormalities. Patients with renal impairment (serum creatinine >2 mg/dL) also achieved similar improvements in PFS at 60 months (32% vs 5%; P = .001) and OS at 60 months (66% vs 21%; P <.001). Based on these results, the authors concluded that bortezomib-based induction and maintenance was associated with significant and durable survival improvements, and may significantly reduce the unfavorable effects of del(17p) and renal impairment on survival of patients with newly diagnosed MM.

  1. Sonneveld P, et al. J Clin Oncol. 2012;30:2946-2955.
  2. Sonneveld P, et al. ASH 2015. Abstract 27
Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017